Prevail Therapeutics

30 articles about Prevail Therapeutics

• 

  Lilly’s Prevail, Doudna’s Scribe Partner on Genetic Treatments for Neuro Dise...

  5/17/2023

  The $75 million deal will leverage Scribe’s CRISPR technologies to develop gene therapies for neurological and neuromuscular disorders. Scribe previously struck deals with Biogen and Sanofi.

• Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Develop Non-Invasive Gene Therapies for CNS Diseases

  1/4/2023

  Capsida Biotherapeutics Inc. ("Capsida") today announced a multi-year strategic collaboration with Prevail Therapeutics ("Prevail"), a wholly owned subsidiary of Eli Lilly and Company ("Lilly"), to develop transformative genetic medicines for serious diseases.

• 

  Lilly Pumps $700M into Boston-Based RNA Therapeutics Facility

  2/22/2022

  Eli Lilly is investing $700 million to build a state-of-the-art facility in Boston, as part of plans to advance its RNA-based therapeutics research and development activities. 
• 

  Omega's New Fund Has $650 Million to Invest in Life Science Companies

  12/17/2021

  Omega raised $650 million, which it plans to invest in life science companies in the U.S. and Europe. 
• 

  Biopharma is Tackling Misfolding Proteins in Parkinson’s Disease

  12/2/2021

  Parkinson’s disease has been immensely challenging for biotech companies. A high rate of late-stage attrition in trials has led to a lack of approved therapies for the disease.

• Lilly Completes Acquisition of Prevail Therapeutics

  1/22/2021

  Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL)

• Lilly Announces Agreement to Acquire Prevail Therapeutics

  12/15/2020

   Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 million)

• Prevail Therapeutics to Present at Upcoming Investor Conferences - Nov 10, 2020

  11/10/2020

  Prevail Therapeutics Inc., a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, will participate in the following virtual investor conferences in November and December:

• 

  Prevail and Alector Both Declare Victory in Year-Long Legal Battle

  11/4/2020

  Both sides claim to be pleased with arbitration results in dispute over Prevail CEO's alleged breach of contract from time with Allector.

• Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher Disease

  10/27/2020

  Prevail Therapeutics Inc., a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, announced that the U.S. Food and Drug Administration has granted Fast Track designation for the Company’s experimental gene therapy program, PR001, for the treatment of neuronopathic Gaucher disease.

• Prevail Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights

  8/11/2020

  Preliminary Data Demonstrates Normalization of CSF GBA1 Enzyme Activity in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease Patients

• Prevail Therapeutics Appoints Kira Schwartz, J.D., as General CounselMs. Schwartz brings over 16 years of legal experience in the biopharma industry to Prevail’s leadership team

  6/4/2020

  Prevail Therapeutics Inc., a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, announced the appointment of Kira Schwartz, J.D., as the Company’s General Counsel.

• Prevail Therapeutics to Present at The Jefferies 2020 Virtual Global Healthcare Conference

  5/26/2020

  Prevail Therapeutics Inc., a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer, will present a company overview at the upcoming Jefferies Virtual Global Healthcare Conference on Tuesday, June 2, 2020 at 3:30 p.m. ET.

• Prevail Therapeutics Reports First Quarter 2020 Financial Results and Business Highlights

  5/14/2020

  Prevail Therapeutics Inc., a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, reviewed recent business highlights and reported financial results for the first quarter ended March 31, 2020.

• Prevail Therapeutics to Present at Bank of America Global Research Virtual Health Care Conference 2020

  5/5/2020

  Prevail Therapeutics Inc. announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer, will participate in a fireside chat at the Bank of America Global Research Virtual Health Care Conference 2020 on Tuesday, May 12, 2020 at 11:40 a.m.

• Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR006 to Slow the Progression of Frontotemporal Dementia with a GRN Mutation

  3/24/2020

  Prevail Therapeutics Inc. announced that the U.S. Food and Drug Administration has granted Fast Track Designation for the Company’s experimental gene therapy program, PR006, to slow the progression of frontotemporal dementia with a GRN mutation.

• 

  Six Biotech Companies with IPOs This Week

  6/21/2019

  This week marked initial public offering news from six biopharma companies. Here’s a look.

• Prevail Therapeutics Announces Pricing of Initial Public Offering

  6/20/2019

  Prevail Therapeutics Inc. announced the pricing of its initial public offering of 7,353,000 shares of its common stock at a price to the public of $17.00 per share.

• Prevail Therapeutics Announces IND Active for Phase 1/2 Trial of its Gene Therapy PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations

  6/4/2019

  Prevail Therapeutics Inc., a gene therapy company developing AAV-based gene therapies for patients with neurodegenerative diseases, today announced the U.S. Food and Drug Administration has accepted the Company’s Investigational New Drug application for its lead gene therapy program, PR001.

• 

  BioSpace Movers and Shakers, May 17

  5/17/2019

  Biopharma companies add new leaders to executive roles and boards of directors.